2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Immunology, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5303 Risk-adapted first-line CAR T-cell consolidation following chemotherapy-free induction and limited cytarabine in newly diagnosed mantle cell lymphoma: A Phase 2 study

Yuting Yan, MD, Weihao Chen2, Xinyi Zhang3, Ying Yu4, Tingyu of Wang5, Wenjie Xiong6, Liang Wang Sr, MD, PhD7, Liang Huang, MD8, Wei LIU9, Dehui Zou, MD10, Gang An, MD11, Lu-Gui Qiu, PhD12, Shuhua Yi, DO13
1 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 Shengli Oilfield Central Hospital, Dongying, China
8 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
9 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
11 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
12 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
13 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Background: High-risk mantle cell lymphoma (MCL) is characterized by early relapse despite intensive frontline therapy. Moving CAR T-cell therapy from the relapsed/refractory setting into planned first-line consolidation may intercept resistant disease before relapse, but prospective experience is limited. We evaluated chemotherapy-free induction with obinutuzumab, zanubrutinib, and lenalidomide (ZGR), followed by limited cytarabine-containing consolidation and planned, risk-adapted first-line CAR T-cell therapy for patients with high-risk disease.

Methods: This prospective, open-label, single-center phase 2 study (NCT06504199) enrolled previously untreated patients with pathologically confirmed MCL. Participants received six 28-day cycles of ZGR (obinutuzumab 1000 mg, zanubrutinib 160 mg twice daily, and lenalidomide 20 mg on days 1-21), followed by up to three cycles of obinutuzumab plus cytarabine. Patients with protocol-defined high-risk disease (high-risk MIPI-c, blastoid/pleomorphic morphology, TP53/CDKN2A/MYC alterations, or non-CR) were offered planned first-line CAR T-cell consolidation before zanubrutinib-lenalidomide maintenance. The primary endpoint was complete response rate (CRR) by Lugano 2014 criteria after induction/consolidation in the full analysis set (FAS; all patients receiving at least one study dose). Secondary endpoints included overall response rate (ORR), marrow measurable residual disease (MRD) negativity, progression-free survival (PFS), overall survival (OS), and safety.

Results: Forty patients received study treatment. Median age was 58.5 years (range, 38-74), 32 (80.0%) were male, 38 (95.0%) had stage III-IV disease, and 10 (25.0%) had high-intermediate/high MIPI risk. Eight of 39 tested patients (20.5%) had a TP53 abnormality; among 30 patients with recorded morphology, 8 had blastoid/pleomorphic disease. FAS CRR and ORR were 52.5% and 82.5% after three ZGR cycles and 90.0% and 92.5% after six cycles, respectively. End-of-treatment CRR and ORR were both 95.0% (38/40; 95% CI, 83.5-98.6), with 2 PD; supportive CRR excluding the early PD was 97.4% (38/39). Among the remaining 39 patients, all completed at least three ZGR cycles; 37 completed six recorded ZGR cycles. Cytarabine exposure was 0, 1, 2, and 3 cycles in 5, 6, 1, and 27 patients, respectively. Five patients (12.5% of FAS) with protocol-defined high-risk disease, including 4 with blastoid/pleomorphic morphology and 2 with TP53 abnormalities (overlapping), received planned first-line CAR T-cell consolidation while in response. At cutoff, all 5 were in CR, had entered maintenance, and remained progression-free after a median observation from enrollment of 30.6 months (range, 28.9-36.9); overall, 33 patients entered maintenance. Among 34 patients with baseline marrow involvement, 28 had at least one postbaseline marrow MRD assessment and all were negative; at the six-cycle landmark, 19/19 evaluable samples were MRD negative. PET-CT showed Deauville scores 1-2 in all 23 evaluable patients. As of August 3, 2026, median observed follow-up was 25.6 months. With 2 confirmed PFS events and 2 deaths, 12- and 24-month PFS were both 95.0% (95% CI, 81.5-98.7); 12- and 24-month OS were 97.5% and 94.9%, respectively. Both PFS events occurred in patients with TP53-abnormal blastoid/pleomorphic disease who received 0-1 cytarabine cycles.

Conclusions: Frontline ZGR followed by limited consolidation produced a 95.0% FAS CRR and deep MRD and metabolic responses without mandatory autologous stem-cell transplantation. Importantly, this study provides prospective proof-of-concept for moving CAR T-cell therapy into planned first-line consolidation for biologically high-risk MCL: all 5 treated high-risk MCL patients remained in CR and progression-free at a median observation of 30.6 months. This small, nonrandomized CAR T-cell cohort is hypothesis-generating and warrants prospective expansion alongside longer follow-up and complete safety reporting.

Yuting Yan, MD: No relevant conflicts of interest to declare.